drugset / Trial / NCT03246555

Fimasartan in the Senior Subjects

NCT03246555 ↗

Phase 3 Completed 241 enrolled Boryung Pharmaceutical Co., Ltd
RandomizedParallel-groupTriple-blindTreatment

Summary

The objective of this study is to confirm the noninferiority of the blood pressure lowering effect of fimasartan and evaluate its safety compared to perindopril in the elderly with essential hypertension.

Timeline

Start
2016-07-15
Primary completion
2019-08-19
Completion
2019-12-09

Outcome

Met primary endpoint

paper The difference between the 2 groups was 5.4 (2.1) mm Hg, indicating the noninferiority of fimasartan to perindopril. PMID 34503866 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Fimasartan Small molecule 30 mg —
Subject Fimasartan Small molecule 60 mg —
Subject Hydrochlorothiazide Unknown 12.5 mg —
Comparator Indapamide Small molecule 1.25 mg —
Comparator Perindopril Small molecule 2.5 mg —
Comparator Perindopril Small molecule 5 mg —

Indications

No indication recorded.